Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant - Wikidata - awgldk - TriplyDB

Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant

Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant

http://www.wikidata.org/entity/Q24655036

about

Radiotherapy combination opportunities leveraging immunity for the next oncology practice Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities Therapeutic cancer vaccines: past, present, and future Radiation meets immunotherapy - a perfect match in the era of combination therapy?Vaccines versus immunotherapy: overview of approaches in deciding between options In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer The 4q27 locus and prostate cancer risk.A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer Strategies for cancer vaccine development.Vaccines as monotherapy and in combination therapy for prostate cancer.Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways.Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.Exploiting synergy: immune-based combinations in the treatment of prostate cancer.High SEPT9_i1 protein expression is associated with high-grade prostate cancers Therapeutic cancer vaccines: current status and moving forward.Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.Multidimensional glycan arrays for enhanced antibody profiling Current perspectives in prostate cancer vaccines Combining radiation and immunotherapy for synergistic antitumor therapy.Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges Poxviral vectors for cancer immunotherapy Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice Therapeutic cancer vaccines: the latest advancement in targeted therapy.Therapeutic vaccines: the ultimate personalized therapy?Promising novel immunotherapies and combinations for prostate cancer Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.Combination approaches to immunotherapy: the radiotherapy example.Ipilimumab in prostate cancer.Prostate cancer vaccines in combination with additional treatment modalities.Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant.

P2860

Q26738443-1B087F90-5FCC-4C80-92F2-6EEED878EC58 Q26851710-CAF73328-7775-4500-A450-9BDEA0977BBA Q26863283-008F4E20-1F5C-468C-B2A5-AF7D35F299D3 Q27005913-9E125C99-8303-4FAE-9635-4A39D789B0A5 Q28085434-FC530411-2BC4-4B51-A5DE-51C4F7719C42 Q28390899-7F3CCCA3-827D-474A-B5BA-42786FC2D8F6 Q33534461-E0C1DD10-DBC8-49A6-9966-5266935B4735 Q33609458-D7B34491-A202-469B-84EB-4F097A217F5E Q33627023-4451BBFD-AB24-4BD0-B003-4AE52E1ED07D Q33645792-32619EF3-0E86-47AB-BF14-3B7B3DC07EA4 Q33712858-B2E8C145-4681-4D78-9A3B-0A0663B80FA5 Q34038338-A3B50128-8AF9-41D5-A2CF-890E16EC19D7 Q34039068-8D9758FE-D2D4-4DFA-9B7D-C633AD0DC3B1 Q34184469-DFF227C6-8751-4D5A-AF4F-B0AED110A4AF Q34333155-B6A11D20-34DA-457A-8A34-F74586EE2C0A Q34687216-F0B370F2-00E9-4648-B221-8FA039222D6A Q35610801-276062C4-2D84-47F5-9992-8042D737036F Q35894347-A7D0891B-1216-4E2E-8312-DBC6609CC415 Q35922726-C51145C1-DCCE-4A72-8703-2308F1F39EA8 Q36210670-1A4E2B12-09B6-43AD-9B21-AFAAC9CB26F1 Q36254081-DA8910E5-7882-422D-8BAB-9FB1A625B76C Q36291980-D9DD2F31-C09F-45B5-8D09-B8F14202EB51 Q36317185-51344329-AB7A-4B9F-9FC7-D8B871C120C2 Q36326598-FC5885EB-8B19-4508-9F40-BD55677E708C Q36326713-E216396E-2D1D-4C7F-8286-E4E3908BA525 Q36350388-6F7776C9-8C63-4F1E-BD18-68312334DFA4 Q36430004-3009D5C2-7D34-422F-BA87-C502CE99E6E7 Q36444022-41E8AC33-9BD8-4E19-A099-4814003ADD90 Q36580203-2A5F60F1-A311-4F5D-892D-C42BD11EF926 Q36695629-A41B78FB-AFA7-4A4E-A98D-298B5C0604FE Q36888016-82B72EF4-9841-40F5-83E3-D8825664DFEF Q37250456-AB218705-A6EA-48E6-BE00-958318870369 Q37351567-468D8FE2-C98E-4893-B7BF-DC17E5B7011B Q37676065-E4093396-B0BB-45BA-92E2-CA61D08AD0E8 Q37684364-7AB2B023-F3CF-4323-8856-D04645F78FE6 Q37732958-FAD52A16-D4D7-4B6E-A7C5-0ED164C41EE5 Q37773250-A2184E4A-0B31-4533-81B0-BEE60D846931 Q38069640-93869F2F-0125-47B5-A1A3-98DEE05EEFEE Q38212571-9B1E69B7-DA46-4087-B4FC-FC237489AD49 Q38282887-FF661A95-EC60-4201-8AA5-5E64EE8813C5

P2860

Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant

http://www.wikidata.org/entity/Q24655036

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Safety and immunologic respons ...... eukin 2 is used as an adjuvant

@ast

Safety and immunologic respons ...... eukin 2 is used as an adjuvant

@en

Safety and immunologic respons ...... eukin 2 is used as an adjuvant

@nl

type

label

Safety and immunologic respons ...... eukin 2 is used as an adjuvant

@ast

Safety and immunologic respons ...... eukin 2 is used as an adjuvant

@en

Safety and immunologic respons ...... eukin 2 is used as an adjuvant

@nl

prefLabel

Safety and immunologic respons ...... eukin 2 is used as an adjuvant

@ast

Safety and immunologic respons ...... eukin 2 is used as an adjuvant

@en

Safety and immunologic respons ...... eukin 2 is used as an adjuvant

@nl

P1433

Q24655036-74B5A997-1668-402B-A289-45251630498D

P1476

Q24655036-93C75CC6-11CD-4282-B407-5B61CD54BB95

P2093

Q24655036-22F41118-E95A-43EF-9D41-79D1C6E7E143

Q24655036-24026DB5-0112-4497-BFC9-E261E70B7DBE

Q24655036-34C39F93-27C3-45B4-A04D-E805093F5BDE

Q24655036-5D0B7857-97E6-40DE-ABC1-460DD4840C26

Q24655036-92F845E6-4EA7-4583-B2E7-7EDE239532E8

Q24655036-A01F5559-A4AF-4F94-9CD7-5F3D61A75EBE

Q24655036-A8A34E74-1D90-4473-9B1B-032613E086AD

Q24655036-D1F1CDF4-1B28-4D0F-BC36-94F72B115A1F

Q24655036-D9AF0240-AD82-45E6-8B5D-4737E5BB2B4B

Q24655036-FB2F669E-D2AD-4750-A146-DE3F3F3C6070

P2860

Q24655036-0C3EB2FF-65A0-47F7-B0EB-00E4541D8258

Q24655036-0FF33BE4-F4B6-49DD-9FF5-C451FAE2E51D

Q24655036-16ACCBB3-F891-416D-8C19-226040403B06

Q24655036-24449DAD-4EB9-48BE-B729-89B284CAEAC6

Q24655036-33A61383-14F8-4EAD-B0E0-A2EDDEFDE357

Q24655036-36B5F6B5-4841-49B2-A9FD-ED4067FED8A0

Q24655036-36B9196D-AE00-4D89-BAFF-42322633B365

Q24655036-400ECDA1-3AC0-4C12-B17D-2EB311B462F4

Q24655036-4192893F-3621-4290-AFB8-1BCC29D56A27

Q24655036-443E4866-EB88-4C8F-BB0F-E318D8EAEA6F

P304

Q24655036-00F910AB-9069-4D29-807A-5444F39C0C8B

P31

Q24655036-4E923CF1-B3A6-48AB-B3F7-69DB3602938F

P356

Q24655036-7D7A1728-A28F-4532-8529-4F8D8306D289

P407

Q24655036-CBC7B216-DE77-4E84-9D68-C861D5D943A2

P433

Q24655036-2F7B51AC-2D3D-456B-80DA-FF153EF4DBD2

P478

Q24655036-3E2AF273-DE4C-46A4-9766-92AB3CDB06CA

P577

Q24655036-9DE3DA61-D6FC-48EE-83AE-9111FC2EA485

P698

Q24655036-51FA32AC-C201-481E-9F4E-0A493DDED5DA

P921

Q24655036-0086880D-210B-4EC8-A7EB-747C8E1A438B

Q24655036-a5c5b364-6347-4d0e-a14c-a2b9a789d2a5

P932

Q24655036-C38C8811-E68B-4B67-BF13-601F8D2C8D65

P356

1078-0432.CCR-07-5162

P1433

Clinical Cancer Research

P1476

Safety and immunologic respons ...... eukin 2 is used as an adjuvant

@en

P2093

James L Gulley

http://www.w3.org/2001/XMLSchema#string

Jeffrey Schlom

http://www.w3.org/2001/XMLSchema#string

Junko Yokokawa

http://www.w3.org/2001/XMLSchema#string

Kevin Camphausen

http://www.w3.org/2001/XMLSchema#string

Kwong-Yok Tsang

http://www.w3.org/2001/XMLSchema#string

Philip M Arlen

http://www.w3.org/2001/XMLSchema#string

Robert J Lechleider

http://www.w3.org/2001/XMLSchema#string

Seth M Steinberg

http://www.w3.org/2001/XMLSchema#string

Vittore Cereda

http://www.w3.org/2001/XMLSchema#string

William L Dahut

http://www.w3.org/2001/XMLSchema#string

P2860

Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Metronomic scheduling: the future of chemotherapy?

Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

The anti-angiogenic basis of metronomic chemotherapy.

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

Fas and the art of lymphocyte maintenance.

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.

Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

P304

5284-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-5162

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18698048

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

2639763

http://www.w3.org/2001/XMLSchema#string